Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Journalists killed by Israeli strike in southern Lebanon - 26 Famous Cell phone Brands All over The Planet
- 3Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link
- 4Discovery of massive spider's web in Greece reveals unexpected behavior
- 5New movies to watch this weekend: See 'Predator: Badlands' in theaters, rent 'Black Phone 2,' stream Guillermo del Toro's 'Frankenstein' on Netflix
- Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest
- How did Hugh Jackman nail his latest role? Sequins, tighty-whities and embracing 'zero embarrassment.'
- SpaceX shatters its rocket launch record yet again — 165 orbital flights in 2025
- Anti-war protests held across Israel under wartime gathering limits
- 6 Solid Vehicle Fix Administrations to Keep Your Vehicle in Prime Condition
- 9 Under-The-Radar Malaysian Islands To Consider Instead Of Thailand Or Indonesia
- The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find
- Over 1,800 killed since junta seized power in Burkina Faso, rights group says
- Instructions to Really Oversee Unsold SUVs in the Auto Business
